Mortarini R相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers

PEOPLE (NCT03447678) 是一项针对 PD-L1 阴性和低表达晚期非小细胞肺癌患者的一线 II 期帕博利珠单抗试验：临床结果及与循环免疫生物标志物的关联

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2022.100645

Lo Russo, G; Sgambelluri, F; Prelaj, A; Galli, F; Manglaviti, S; Bottiglieri, A; Di Mauro, R M; Ferrara, R; Galli, G; Signorelli, D; De Toma, A; Occhipinti, M; Brambilla, M; Rulli, E; Triulzi, T; Torelli, T; Agnelli, L; Brich, S; Martinetti, A; Dumitrascu, A D; Torri, V; Pruneri, G; Fabbri, A; de Braud, F; Anichini, A; Proto, C; Ganzinelli, M; Mortarini, R; Garassino, M C

细胞生物学

免疫/内分泌

发表日期：2022

文献求助收藏

Correction to: NFATc2 is an intrinsic regulator of melanoma dedifferentiation

更正：NFATc2 是黑色素瘤去分化的内在调节因子

期刊:Oncogene

影响因子:7.3

doi:10.1038/s41388-019-0679-8

Perotti, V; Baldassari, P; Molla, A; Vegetti, C; Bersani, I; Maurichi, A; Santinami, M; Anichini, A; Mortarini, R

发表日期：2019

文献求助收藏

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.

通过共同靶向人类黑色素瘤中的致癌和死亡受体通路，发挥协同抗肿瘤活性并抑制血管生成

期刊:Cell Death & Disease

影响因子:9.6

doi:10.1038/cddis.2014.410

Grazia G, Vegetti C, Benigni F, Penna I, Perotti V, Tassi E, Bersani I, Nicolini G, Canevari S, Carlo-Stella C, Gianni A M, Mortarini R, Anichini A

发表日期：2014

文献求助收藏

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions

转移性黑色素瘤患者外周T细胞群对细胞毒性T淋巴细胞（CTL）定义的黑色素细胞特异性抗原的扩增会影响肽特异性CTL的生成，但并不能克服转移性病灶中肿瘤逃避免疫监视的现象。

期刊:Journal of Experimental Medicine

影响因子:10.6

doi:10.1084/jem.190.5.651

Anichini, A; Molla, A; Mortarini, R; Tragni, G; Bersani, I; Di Nicola, M; Gianni, A M; Pilotti, S; Dunbar, R; Cerundolo, V; Parmiani, G

免疫/内分泌

细胞生物学

发表日期：1999

文献求助收藏

High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition

原发性人类黑色素瘤中T细胞克隆扩增频率高。优势克隆型参与自体肿瘤识别。

期刊:Cancer Immunology Immunotherapy

影响因子:5.1

doi:10.1007/s002620050546

Pisarra, P; Mortarini, R; Salvi, S; Anichini, A; Parmiani, G; Sensi, M

细胞生物学

免疫/内分泌

发表日期：1999

文献求助收藏

Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1

来自不同患者的细胞毒性T淋巴细胞克隆在HLA-A2限制性识别黑色素瘤抗原Melan-A/MART-1方面表现出有限的T细胞受体可变区基因使用。

期刊:Proceedings of the National Academy of Sciences of the United States of America

影响因子:9.1

doi:10.1073/pnas.92.12.5674

Sensi, M; Traversari, C; Radrizzani, M; Salvi, S; Maccalli, C; Mortarini, R; Rivoltini, L; Farina, C; Nicolini, G; Wölfel, T

细胞生物学

免疫/内分泌

发表日期：1995

文献求助收藏

Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients

黑色素瘤细胞和正常黑色素细胞共享一些抗原，这些抗原可被来自黑色素瘤患者的HLA-A2限制性细胞毒性T细胞克隆识别。

期刊:Journal of Experimental Medicine

影响因子:10.6

doi:10.1084/jem.177.4.989

Anichini, A; Maccalli, C; Mortarini, R; Salvi, S; Mazzocchi, A; Squarcina, P; Herlyn, M; Parmiani, G

细胞生物学

免疫/内分泌

发表日期：1993

文献求助收藏

T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone

自体黑色素瘤反应性细胞毒性T淋巴细胞（CTL）克隆的T细胞受体（TCR）结构：肿瘤浸润淋巴细胞在体内过度表达HLA-A2限制性和黑色素细胞谱系特异性CTL克隆所使用的TCR β链序列

期刊:Journal of Experimental Medicine

影响因子:10.6

doi:10.1084/jem.178.4.1231

Sensi, M; Salvi, S; Castelli, C; Maccalli, C; Mazzocchi, A; Mortarini, R; Nicolini, G; Herlyn, M; Parmiani, G; Anichini, A

细胞生物学

免疫/内分泌

发表日期：1993

文献求助收藏